Fierce Biotech

Compass, Usona and Transcend score FDA national priority vouchers amid Trump administration’s psychedelic push

The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...

A Look At COMPASS Pathways (CMPS) Valuation After Regulatory Shift And Phase 3 Psilocybin Results

Why COMPASS Pathways is Back on Investors’ Radar Interest in COMPASS Pathways (NasdaqGS:CMPS) has picked up after a White House executive order aimed at accelerating medical treatments for serious ...

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug ...
Las Vegas Sun

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based ...
Zacks Investment Research on MSN

Is Compass Pathways (CMPS) outperforming other medical stocks this year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is COMPASS Pathways PLC Sponsored ADR (CMPS) one of those stocks right now? A quick ...
Hosted on MSN

FDA grants Compass Pathways priority voucher for psilocybin drug

The FDA has awarded Compass Pathways a priority review voucher and rolling submission for its COMP360 psilocybin therapy for treatment-resistant depression, potentially cutting review time to one or ...
Agence France-Presse

Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments

Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of ...
Blockonomi

COMPASS Pathways (CMPS) Stock Soars 25% on Trump’s Psychedelics Research Order

COMPASS Pathways (CMPS) stock jumped 25% after Trump's executive order on psychedelic research. Positive Phase 3 data boosts ...
TMCnet

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

In accordance with NASDAQ Listing Rule 5635 (c) (4), the equity awards were approved by the Compensation and Leadership Development Committee of Compass's Board of Directors and were made as a ...
Investing.com South Africa

Compass Pathways shares rise as FDA grants rolling review for depression drug

Investing.com - Compass Pathways plc (NASDAQ:CMPS) said Thursday the U.S. Food and Drug Administration granted the company a rolling New Drug Application review for COMP360, its synthetic psilocybin ...
Seeking Alpha

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...